NCT05793489View on ClinicalTrials.gov

Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin

NAActive, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

April 4, 2025

Study Completion Date

March 30, 2026

Conditions
Brain Metastases, Adult
Interventions
OTHER

Silibinin

"WBRT will be concomitant to Silibinin. Silibinin at dose of 500 mg must be administrated twice a day for the first month, after once a day continuously.~Total dose and fractionation of WBRT: 30 Gy in 10 fractions."

Trial Locations (1)

20089

IRCCS Humanitas Research Hospital, Rozzano

All Listed Sponsors
collaborator

health4u S.R.L

UNKNOWN

lead

Istituto Clinico Humanitas

OTHER